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Objectives.
1. Audit adequacy of admission screening for MRSA in vascular surgery patients.
2. Establish the prevalence of MRSA carriage at the time of admission in emergency/transfer and elective patients.
3. Establish a threshold prevalence of MRSA that should trigger the use of prophylactic antibiotics active against MRSA.
4. Model some of the costs and efficacy of glycopeptides such as vancomycin, compared to aminoglycosides such as
gentamicin, for the prevention of MRSA surgical site infections.
Materials and Methods. 200 consecutive emergency/transfer and 150 consecutive elective patients admitted between
April 2004 and January 2005, were studied. Data was obtained from departmental Morbidity and Mortality records
and the computerised laboratory medicine information system.
Results. 261 (75%) of the 350 patients were screened for MRSA on admission (target 100%). The proportions of emer-
gency/transfer and elective patients screened were similar (78% and 72% respectively). The prevalence of MRSA carriage
detected by admission screening in emergency/transfer patients 30/153 (20%), was significantly higher (p< 0.0001) than
in elective patients 2/108 (2%).
A simple decision analysis model suggests that gentamicin should be used when the prevalence of MRSA reaches 10% and
vancomycin when the prevalence reaches 50%.
Conclusions. The high prevalence of MRSA colonisation in emergency/transfer patients has important implications for
pre-operative antibiotic prophylaxis.
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Surgical site infection is a rare but devastating event
for the vascular patient. This may involve the wound
or a graft or both. Graft infection is particularly seri-
ous occurring at a frequency of 1e6%.1,2 Treatment
usually requires re-operation, prolonged hospital
stay and long term antibiotic therapy. Even with
such interventions morbidity and mortality remain
high. Approximately 30% of patients with aortic graft
infection die and 20% lose a limb.3 Around 17% of
patients with femoro-popliteal graft infection die and
up to 50% require amputation.3
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has become a major hospital-acquired pathogen in
many countries including the UK over the past 15
years.4,5 In addition, it is now recognised as a commu-
nity pathogen,6,7 with MRSA accounting for 24% of
community acquired Staphylococcus aureus bacterae-
mia in the catchment of our hospital.8 Most surgical
site infections after vascular procedures are caused
by Staphylococcus aureus, although graft infections
may involve Coagulase Negative Staphylococci.9 Re-
cent audits in the UK show that up to 55% of deep
wound and graft infections are caused by Staphylococ-
cus aureus and that 70% of isolates from surgical sites
are MRSA.9,10 Infection with MRSA is associated with
a poor outcome in vascular surgery patients, with
higher rates of amputation after arterial reconstruc-
tion in the leg as compared with methicillin-sensitive
Staphylococcus aureus (MSSA) infection.9 MRSA aorticrved.
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ity rates.11
Because of the serious consequences of MRSA
infection in vascular surgery patients, screening for
the organism prior to or on admission is recom-
mended.11,12 Although results of admission screening
only become available 3 days or more following
admission, they provide useful information to guide
empirical therapy should the patient develop a post
operative infection, and to reinforce procedures such
as isolation or cohort nursing designed to prevent
spread of MRSA to other patients.13 This information
can also be used, when aggregated at the population
level, to ensure that prophylactic antibiotic regimens
are appropriately targeted.11 The cost effectiveness
of this strategy has been demonstrated in both the
US and European healthcare systems.14 In our unit it
is policy to screen all vascular patients for MRSA
within 48 hours of admission.
Antibiotic prophylaxis is recommended for all vas-
cular surgical procedures.15 In the UK, b-lactams such
as a first or second generation cephalosporin or co-
amoxiclav are often used, with aminoglycosides like
gentamicin employed as an alternative for patients al-
lergic to b-lactams.9,15 Prophylaxis for the prevention
of surgical site infections caused by MRSA, which is
inherently resistant to all b-lactams, is not universal,
though many specialists advise the use of glycopep-
tides (vancomycin or teicoplanin) in patients at high
risk of MRSA associated complications.9,11,15e17 High
risk situations include surgery in patients known to
have MRSA; re-operation for graft infection; re-
exploration of sites adjacent to prosthetic grafts and
units with high baseline rates of MRSA.11,18 The fre-
quency of MRSA carriage in patients admitted for
vascular procedures is not well documented, and is
likely to change over time and place.13 Recently
a prevalence of >10% MRSA carriage in the popula-
tion receiving prophylaxis has been suggested as
a trigger for the use of glycopeptides.19 However the
widespread use of glycopeptides has several dis-
advantages. Excessive use is linked to the emergence
of vancomycin-resistant Enterococci and Staphylo-
coccus species for which there are few therapeutic
options.19,20 Vancomycin needs to be infused over an
hour and hence must be started on the ward prior
to theatre. If rapidly infused it may cause hypotension
and histamine release which may have adverse effects
during anaesthesia.21,22 Teicoplanin is an alternative
but is very costly (British National Formulary (BNF)
cost £35.62 for 400 mg compared to £17.32 for vanco-
mycin 1 g). These issues have led to calls for a re-
examination of the role of aminoglycosides such as
gentamicin for MRSA prophylaxis.19 Gentamicin isusually used for its potent activity against Gram
negative organisms such as E. coli and Pseudomonas
aeruginosa, with typical minimum inhibitory concen-
trations (MICs) of 1e4 mg/L and 1e8 mg/L respec-
tively. However it is also highly active against most
strains of Staphylococcus aureus including common
UK strains of MRSA (MIC 0.12e1 mg/L).23 A bolus
of 1.5 mg/Kg at induction gives a peak serum concen-
tration of 5e10 mg/L, exceeding the MIC for MRSA
and MSSA by 5e10 fold.23 Gentamicin resistance in
MRSA is a well described but minor problem and
currently 91% of MRSA strains in the UK are suscep-
tible.24 Gentamicin can be given by bolus at induction,
intra operative top ups are not required because of its
longer half-life compared to cefuroxime,25 and it is
cheap (BNF cost £4.20 for 120 mg).
We therefore decided: firstly to audit the adequacy
of admission screening for MRSA. Secondly to estab-
lish the prevalence of MRSA carriage at the time
of admission in elective and emergency/transfer
patients. Thirdly to establish a threshold prevalence
of MRSA which should trigger the use of prophylactic
antibiotics active against MRSA, by modelling the ex-
pected burden of MRSA surgical site infections when
using b-lactam antibiotics such as cefuroxime, which
are not active against MRSA, for prophylaxis. Lastly,
to model the efficacy of glycopeptides such as vanco-
mycin, compared to aminoglycosides such as genta-
micin, for the prevention of MRSA surgical site
infections.
Materials and Methods
Records of all vascular patients were obtained retro-
spectively from departmental Morbidity and Mortal-
ity meeting data sheets, which log all vascular
patients admitted to the John Radcliffe Hospital. Be-
tween April 2004 and January 2005, 150 consecutive
elective admissions (admitted from the community
for a planned surgical intervention), and 200 emer-
gency/transfer admissions (patients admitted via the
Emergency Department or transferred from neigh-
bouring regional hospitals) were included in our
study.
Differences in prevalence of MRSA carriage
between the two groups of patients were compared
using the chi squared test (STATA 8.2 software).
Our departmental policy was to screen all vascular
patients admitted to our unit by culturing nose,
throat, axillae, perineum and wound swabs for
MRSA. Culture included enrichment as recommen-
ded by the English Health Protection Agency.26 If
the patient was catheterised a urine sample was alsoEur J Vasc Endovasc Surg Vol 32, October 2006
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taken within 48 hours of admission. Patients whose
admission screen was negative and where MRSA
was cultured from any specimen taken to investigate
clinical infection after 48 hours of hospital stay were
classed as ‘acquisitions’ (i.e. having acquired MRSA
in hospital). This 48-hour cut off is widely used by ep-
idemiologists to define hospital-acquired infection.27
The MRSA admission screening status and the results
of all subsequent microbiology tests performed was
obtained from the computerised laboratory medicine
information system.
A simple decision analysis was used to calculate
the number of MRSA wound infections expected at
a given prevalence of MRSA in the two groups under-
going surgery28:
Assumptions underlying the decision analysis
The proportion of vascular wound infections
caused by Staphylococcus aureus is 75%.1,9
The wound infection rate when no effective anti-
biotic prophylaxis is given is 15%.16,29
The relative risk reduction in rate of post operative
wound infection with effective antibiotic prophy-
laxis is 66% (15%/ 5%)16,29e33
Vancomycin is 100% effective against MRSA
in vitro.19
Gentamicin is at least 80% effective against MRSA
strains in the UK in vitro.24
Cefuroxime is ineffective against MRSA in vitro.19
Model of efficacy of antibiotic prophylaxis in prevention
of wound infection in vascular surgery
Let the proportion of wound infections caused by
Staphylococcus aureus¼W
Let risk of wound infection with inappropriate or
no antibiotic prophylaxis¼ I
Let the relative reduction in risk of wound infection
with appropriate prophylaxis¼R
Let the prevalence of MRSA in the population re-
ceiving prophylaxis¼ P
Let the proportion of MRSA strains susceptible to
the prophylaxis¼ S
Therefore, the reduction in the risk of wound
infection caused by MRSA for any antibiotic pro-
phylactic regimen¼WIRPS
Therefore, the number needed to treat (NNT)¼
1/WIRPS
See Appendix for worked example.Eur J Vasc Endovasc Surg Vol 32, October 2006The model was used to examine some of the costs and
effectiveness of three different prophylactic antibiotic
regimens (cefuroximeþ vancomycin, cefuroximeþ
gentamicin, and vancomycinþ gentamicin) for the
prevention of post-operative wound infection caused
by MRSA. Cost of antibiotics was calculated using
the British National Formulary (BNF).
Results
Elective admissions
Of the 150 patients (M:F 2.8:1, median age 67, range
54e83) in this group, 108 (72%) had evidence of
appropriate MRSA admission screening. Only 2 (2%)
patients of the 108 screened were colonised with
MRSA. No elective patients acquired MRSA during
their hospital stay.
Emergency/transfer admissions
Of 150 emergency patients (M:F 2.2:1, median age 64,
range 36e91), 119 (79%) were screened on admission,
and of these 26 (22%) were colonised with MRSA. Of
50 patients (M:F 2.3:1, median age 63, range 39e76)
transferred from other hospitals, 34 (68%) were
screened on admission, and of these 4 (12%) were
colonised with MRSA. Because the number of transfer
patients was small, their results were combined with
the emergency patients. Of the 200 emergency/
transfer patients 153 (77%) were screened for MRSA
on admission. and 30 (20%) were colonised with
MRSA. Seven (6%) of the 123 patients who screened
negative for MRSA on admission, acquired the organ-
ism during their stay.
The prevalence of MRSA assessed on admission in
emergency/transfer patients (30/153 20%) was signif-
icantly higher than in elective patients (2/108 2%)
(Odds Ratio 12.9 CI 3.1e113.4 c2 18.6 p< 0.0001).
Using the decision analysis model the number-
needed-to-treat (NNT) to prevent a single MRSA
surgical site infection for the two groups using a vari-
ety of prophylactic antibiotic regimens was calculated
(Table 1, Fig. 1).
In the pre MRSA era the prevalence of MSSA
carriage in the general population was 10e20%.34
Using cefuroxime (with 100% activity against MSSA)
the NNT to prevent a single MSSA wound infection
in vascular surgery was therefore in the order of 135
to 67 (Table 1, Fig. 1). This range of NNTs can be
regarded as the ‘gold standard’ for prophylaxis in
the pre MRSA era.
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developing an MRSA surgical site infection in an
elective patient in our unit, with carriage rates of
2%, is calculated to be 0.00225 (0.75 0.15 0.02 see
Appendix) or 1 infection for every 444 elective
patients undergoing surgery. For our emergency/
transfer patients with a carriage rate of 20%, the risk
is tenfold higher, 0.0225 or 1 in 44. This corresponds
to a potential burden of 6 MRSA surgical site infec-
tions in the 265 emergency/transfer patients admitted
to our unit each year, at a cost of £12,225 assuming
a cost of £2,017 per infection.35 The NNT for vancomy-
cin prophylaxis to prevent a single MRSA surgical site
infection in the elective group is 673, and in the trans-
fer/emergency group 67 (Table 1, Fig. 1). Since the
NNT for cefuroxime used in populations carrying
MSSA is in the order of 135 to 67, the use of vancomy-
cin would be justified for our emergency/transfer
patients but not those undergoing elective surgery.
At a prevalence of 20%, £1,166 (67 £17.32) spent on
Table 1. Table showing number of patients needed to treat (NNT)
to prevent a single MRSAwound infection for 3 different prophy-
lactic antibiotic regimens, according to the prevalence of MRSA
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Fig. 1. Graph showing number of patients needed to treat
(NNT) to prevent a single MRSA wound infection for 3 dif-
ferent prophylactic antibiotic regimens, according to the
prevalence of MRSA in the target population.vancomycin in emergency/transfer patients will pre-
vent one MRSA surgical site infection costing £2,017.
In elective patients, where the MRSA prevalence is
only 2%, the cost of vancomycin would be £11, 656
(673 £17.32) for each infection prevented.
Given the ecological and financial costs, and the
logistical problems of glycopeptide prophylaxis we
used the model to examine the efficacy of gentamicin
in our patients. We assumed gentamicin was active
against 80% of MRSA, a conservative estimate given
that in our unit over the study period it was active
against 94% of MRSA cultured from admission
screens. The NNT for gentamicin to prevent a single
MRSA surgical site infection in our elective group is
842, and 84 in the transfer/emergency group (see
Table 1). Gentamicin is therefore an attractive option
for MRSA prophylaxis in emergency/transfer patients,
allowing glycopeptides to be targeted to those
patients known to be MRSA colonised at the time
surgery, where the NNT for vancomycin is 13 (Table 1
MRSA prevalence 100%). In units using gentamicin
in this way, the model suggests there is little benefit
to using glycopeptide prophylaxis other than for
patients known to be colonised with MRSA at
surgery. For example, in our emergency/transfer
patients, the NNT to prevent an MRSA surgical site
infection when adding vancomycin to a prophylactic
regimen that includes gentamicin is estimated to be
337, greater than the ‘gold standard’ NNT of the
pre MRSA era of 135 for cefuroxime used against
MSSA strains. However when the prevalence of
MRSA colonisation reaches 50%, using vancomycin
for all patients may be beneficial, as the NNT for
its use in addition to gentamicin is 135 (Table 1),
equivalent to the ‘gold standard’ NNT for routine
cefuroxime prophylaxis for MSSA.
Discussion
Approximately 3 out of 4 patients admitted to our
unit are screened for MRSA in accordance with our
unit policy. We found no evidence that compliance
with admission screening was influenced by staff
perception of risk of MRSA carriage in the two pop-
ulations studied. The proportion screened in each
group was similar: elective 108/150 (72%) and emer-
gency/transfer 153/200 (78%), rates similar to those
recently reported in two adult intensive care units in
the UK.36
The overall prevalence of MRSA carriage in pa-
tients admitted to our unit and screened was 32/261
(12%), higher than the 4% documented in patients
admitted to the Leicester UK vascular unit in 2002.13Eur J Vasc Endovasc Surg Vol 32, October 2006
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time, since the MRSA epidemic in the UK and Europe
is still evolving,37 so it is important for each unit to
collect local data to inform decisions about antibiotic
prophylaxis. We found the prevalence of MRSA in
emergency/transfer patients (20%) to be significantly
higher than elective patients (2%) p< 0.0001. We did
not collect risk factor data but our emergency/transfer
vascular patients often have critical ischaemia with
skin ulceration and a history of prior hospital admis-
sion which are risk factors for MRSA colonisation.11
The majority of our elective patients do not have these
risk factors. Typically they include patients with clau-
dication (not rest pain), abdominal aortic aneurysm
and carotid stenosis. It is noteworthy that elective
patients, who would be available for pre admission
screening, have a low MRSA carriage rate. The emer-
gency/transfer patients, who by dint of their condi-
tion are not available for pre admission screening,
have a high rate.
Decision analysis has been used to examine the cost
and efficacy of antibiotic prophylaxis in a neurosurgi-
cal unit where the prevalence of MRSA in patients
transferred into the unit was found to be 15%.28 A
combination of cefuroxime and gentamicin was found
to be satisfactory for these patients, with vancomycin
reserved for patients known to be colonised or in-
fected with MRSA.28 Our model is not definitive or
comprehensive. The number of variables has been
kept small, we did not carry out a sensitivity analysis
to explore the relative impact of each variable on the
outcome (NNT), and we did not look at all possible
costs and benefits. However, in practice such sophisti-
cation is not needed since the aim is to guide rather
than determine policy. Antibiotic prophylactic regi-
mens in our unit were changed on the basis of the
data and model presented here. The 10% threshold
prevalence of MRSA for modification of prophylaxis
to include gentamicin, suggested by our model, is in
accordance with the 10% threshold recently advised
by a working part of the British Society of Antimicro-
bial Chemotherapy.19
MRSA carriage is uncommon in our elective vascu-
lar surgery patients (2%), and the yield of pre admis-
sion screening recommended by some12 would be
correspondingly low. Our model shows that b-lactam
prophylaxis for this patient group is likely to be safe.
MRSA carriage is common (20%) in vascular surgery
patients admitted as an emergency or transferred
from another hospital to our unit. The MRSA status
of these patients cannot reliably be determined before
admission, and since the results of admission MRSA
screening are not available for 3 or more days, they
usually undergo surgery when their MRSA status isEur J Vasc Endovasc Surg Vol 32, October 2006unknown. Our model suggests that using b-lactam
antibiotics, such as cefuroxime, for prophylaxis in
this group would lead to an unacceptable burden of
MRSA surgical site infection. Aminoglycosides such
as gentamicin are an attractive option for these
patients and other populations where the prevalence
of MRSA is between 10 and <50%, allowing glyco-
peptides to be targeted to those known to be colonised
with MRSA. This is in keeping with the 10% preva-
lence threshold recently suggested by a working party
of the British Society of Antimicrobial Chemother-
apy.19 When the prevalence of MRSA reaches 50%,
vancomycin is likely to be a safer option (NNT 135).
However our model is a simple one and needs to be
validated by formal cost benefit analysis.
The prevalence of MRSA colonisation in patients
admitted to hospitals in the UK is increasing and
probably varies geographically.37 Vascular teams
should therefore conduct their own local studies of
MRSA prevalence to ensure their prophylactic anti-
biotic regimens are targeted appropriately. We have
shown how decision analysis can be used to achieve
this targeting once the prevalence data is known.
There is a pressing need to validate such models
with randomised controlled trials comparing amino-
glycosides and glycopeptides for prophylaxis in
vascular patients with high rates of MRSA carriage.
Appendix.
Decision analysis used to determine risk of wound
infection and NNTs with different prophylactic anti-
biotic regimens.
Worked Example
NNT calculation for efficacy of Gentamicin prophy-
laxis to prevent a single MRSA wound infection in
a vascular surgery patient population where the
MRSA carriage rate is 20%:
Proportion of wound infections caused by Staphylo-
coccus aureus¼W[ 0.75
Risk of wound infection with inappropriate or no
antibiotic prophylaxis¼ I[ 0.15
Relative reduction in risk of wound infection with
appropriate prophylaxis¼R[ 0.66
Prevalence of MRSA in the population receiving
prophylaxis¼ P[ 0.2
Proportion of MRSA strains susceptible to the
prophylaxis¼ S[ 0.8
NNT[ 1/WIRPS[ 84
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